Chen Nan-Xiang, Chen Lei, Wang Jia-Ling, Wang Jin-Yuan, Yan Fang, Ma Lin, Zhang Xin-Xin
Department of Otorhinolaryngology/Head and Neck Surgery, Chinese People's Liberation Army General Hospital, Beijing.
Department of Radiation Oncology, Chinese People's Liberation Army General Hospital, Beijing, PR China.
Jpn J Clin Oncol. 2016 Aug;46(8):727-34. doi: 10.1093/jjco/hyw064. Epub 2016 May 20.
This study aimed to investigate the efficacy of induction chemotherapy followed by concurrent chemotherapy and helical tomotherapy in patients with T4b squamous cell carcinoma of the nasal cavity and paranasal sinus in regard to orbital organ preservation and quality of life.
Clinical data of 28 cases of patients with orbital involvement of T4b squamous cell carcinoma of the nasal cavity and paranasal sinus who received multimodal treatment for orbital organ preservation between May 2008 and September 2015 were retrospectively analysed. The treatment efficacy and side effects were assessed. The study included 18 male and 10 female patients. All patients were treated with induction chemotherapy followed by concurrent chemoradiotherapy and/or epidermal growth factor receptor inhibitor. Helical tomotherapy was applied as radiotherapy. Adverse reactions to the chemotherapy were assessed according to Common Terminology Criteria for Adverse Events, Version 4. The overall survival rate, local control rate and rate of effective orbital preservation were calculated using the Kaplan-Meier method.
All patients completed the planned chemotherapy, and 27 (96.4%) of the patients completed the planned radiotherapy cycle. After the multimodal treatment, the 3-year overall survival, local control rate and rate of effective orbital preservation of the patients were 59.2%, 80.2% and 77.8%, respectively.
Multimodal treatment could preserve the orbital organs of patients with T4b squamous cell carcinoma of the nasal cavity and paranasal sinus, achieve relatively ideal organ protection and survival rates and improve the quality of life of patients with advanced squamous cell carcinoma of the nasal cavity and paranasal sinus, thus providing a new treatment option for these patients.
本研究旨在探讨诱导化疗后序贯同步化疗及螺旋断层放疗对鼻腔及鼻窦T4b期鳞状细胞癌患者眼眶器官保留及生活质量的疗效。
回顾性分析2008年5月至2015年9月间接受多模式治疗以保留眼眶器官的28例鼻腔及鼻窦T4b期鳞状细胞癌眼眶受累患者的临床资料。评估治疗疗效及副作用。研究包括18例男性和10例女性患者。所有患者均接受诱导化疗,随后进行同步放化疗和/或表皮生长因子受体抑制剂治疗。采用螺旋断层放疗作为放射治疗。根据《不良事件通用术语标准》第4版评估化疗不良反应。采用Kaplan-Meier法计算总生存率、局部控制率和有效眼眶保留率。
所有患者均完成了计划的化疗,27例(96.4%)患者完成了计划的放疗周期。多模式治疗后,患者的3年总生存率、局部控制率和有效眼眶保留率分别为59.2%、80.2%和77.8%。
多模式治疗可保留鼻腔及鼻窦T4b期鳞状细胞癌患者的眼眶器官,实现相对理想的器官保护和生存率,提高晚期鼻腔及鼻窦鳞状细胞癌患者的生活质量,从而为这些患者提供一种新的治疗选择。